Pharmacokinetics of T-614 after Single Oral Administration in Healthy Korean Volunteers
![]() |
Shin, Dongseong
(Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Kim, Bo-Hyung (Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital) Kim, Jung-Ryul (Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center) Lim, Kyoung Soo (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) Jang, In-Jin (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) Shin, Sang-Goo (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) Yu, Kyung-Sang (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) |
1 | Kuriyama K, Higuchi C, Tanaka K, Yoshikawa H & Itoh K. A novel anti-rheumatic drug, Iguratimod, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo. Biochem Biophys Resommun, 2002;299(5):903-909. DOI ScienceOn |
2 | Scott DL, Wolfe F & Huizinga TW. Rheumatoid arthritis. Lancet, 2010;376(9746):1094-1108. DOI ScienceOn |
3 | Sawada T, Hashimoto S, Tohma S, Nishioka Y, Nagai T, Sato T, Ito K, Inoue T, Iwata M & Yamamoto K. Inhibition of L-leucine methyl ester mediated killing of THP-1, a human monocytic cell line, by a new anti-inflammatory drug, T614. Immunopharmacology, 2000;49(3):285-294. DOI ScienceOn |
4 | Scrivo R, Di Franco M, Spadaro A & Valesini G. The immunology of rheumatoid arthritis. Ann N Y Acad Sci, 2007;1108(312-322. DOI ScienceOn |
5 | Lu LJ, Teng JL, Bao CD, Han XH, Sun LY, Xu JH, Li XF & Wu HX. Safety and efficacy of Iguratimod in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Chin Med J (Engl), 2008;121(7):615-619. |
6 | Lu LJ, Bao CD, Dai M, Teng JL, Fan W, Du F, Yang NP, Zhao YH, Chen ZW, Xu JH, He PG, Wu HX, Tao Y, Zhang MJ, Han XH, Li XF, Gu JR, Li JH & Yu H. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with Iguratimod compared with methotrexate. Arthritis Rheum, 2009;61(7):979-987. DOI ScienceOn |
7 | van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE & van der Helm-van Mil AH. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with secondgeneration anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum, 2009;60(8):2232-2241. DOI ScienceOn |
8 | Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum, 2002; 46(2):328-346. DOI ScienceOn |
9 | Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A & van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis, 2010;69 (6):964-975. DOI ScienceOn |
10 | Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N & Nobunaga M. Long-term safety study of Iguratimod in patients with rheumatoid arthritis. Mod Rheumatol, 2007;17(1):10-16. DOI |
11 | Smolen JS, Aletaha D, Koeller M, Weisman MH & Emery P. New therapies for treatment of rheumatoid arthritis. Lancet, 2007;370(9602): 1861-1874. DOI ScienceOn |
12 | Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M & Nakano S. Efficacy and safety of Iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol, 2007;17(1):1-9. DOI |
13 | Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR & de Crombrugghe B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell, 2002; 108(1):17-29. DOI ScienceOn |
14 | Tanaka K, Urata N, Mikami M, Ogasawara M, Matsunaga T, Terashima N & Suzuki H. Effect of Iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice. Inflamm Res, 2007;56(1):17-23. DOI |
15 | Carmona L, Cross M, Williams B, Lassere M & March L. Rheumatoid arthritis. Best Pract Res Clin Rheumatol, 2010;24(6):733-745. DOI ScienceOn |
16 | Koch AE. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum, 1998; 41(6):951-962. DOI ScienceOn |
17 | Walsh DA. Angiogenesis and arthritis. Rheumatology (Oxford), 1999;38(2):103-112. DOI ScienceOn |
18 | Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A, Aoyagi T, Furuichi I, Nakashima T, Migita K, Kawabe Y, Nakashima M, Origuchi T & Eguchi K. Inhibitory effect of a new anti-rheumatic drug Iguratimod on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med, 1999;133(6):566-574. DOI ScienceOn |
19 | Tanaka K, Kawasaki H, Kurata K, Aikawa Y, Tsukamoto Y & Inaba T. Iguratimod, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol, 1995;67 (4):305-314. DOI |
![]() |